Masimo Root Monitoring System Gains FDA Clearance

Masimo has gained FDA clearance for its Root Patient Monitoring Platform, a noninvasive, continuous monitoring platform with interoperability and technologies that have demonstrated improved patient safety and cost of care.

Masimo Corp. received FDA 510(k) clearance in June 2014 for its Root Patient Monitoring Platform, a noninvasive, continuous monitoring platform with interoperability that includes technologies that have demonstrated improvements in patient safety and cost of care in clinical studies.

Noninvasive and continuous monitoring devices have been in place for many years. However, the lack of information exchange and integration between monitoring devices can create risks to patient safety as...

More from Archive

More from Medtech Insight